Billie Lynn North, OTR/L in Airville, PA - Occupational Therapist

Billie Lynn North, OTR/L is a Occupational Therapist based in Airville, Pennsylvania. Billie Lynn North is licensed to practice in Pennsylvania (license number OC002209L) and her current practice location is 2624 Holtwood Rd, Airville, Pennsylvania. She can be reached at her office (for appointments etc.) via phone at (717) 887-0241.

NPI number for Billie Lynn North is 1750972279 and her current mailing address is 2624 Holtwood Rd, Airville, Pennsylvania. She does not participate in medicare program and thus does not accept medicare assignments. Her NPI Number is 1750972279.

Contact Information

	Billie Lynn North, OTR/L
	2624 Holtwood Rd, Airville, PA 17302-9100
	(717) 887-0241
	Not Available

Healthcare Provider's Profile

Full Name	Billie Lynn North
Gender	Female
Speciality	Occupational Therapist
Location	2624 Holtwood Rd, Airville, Pennsylvania
Accepts Medicare Assignments	Does not participate in Medicare Program. She may not accept medicare assignment.

NPI Data:

NPI Number: 1750972279
Provider Enumeration Date: 01/27/2021
Last Update Date: 01/27/2021

Medical Identifiers

Medical identifiers for Billie Lynn North such as npi, medicare ID, medicare PIN, medicaid, etc.

Identifier	Type	State	Issuer
1750972279	NPI	-	NPPES

Medical Taxonomies and Licenses

Taxonomy	Type	License (State)	Status
225X00000X	Occupational Therapist	OC002209L (Pennsylvania)	Primary

Medicare Part D Prescriber Enrollment

Any physician or other eligible professional who prescribes Part D drugs must either enroll in the Medicare program or opt out in order to prescribe drugs to their patients with Part D prescription drug benefit plans. Billie Lynn North is NOT enrolled with medicare and thus cannot prescribe medicare part D drugs to patients with medicare part D benefits.

Mailing Address and Practice Location

Mailing Address	Practice Location Address
Billie Lynn North, OTR/L 2624 Holtwood Rd, Airville, PA 17302-9100 Ph: (717) 887-0241	Billie Lynn North, OTR/L 2624 Holtwood Rd, Airville, PA 17302-9100 Ph: (717) 887-0241

News Archive

Health Canada accepts Seattle Genetics' ADCETRIS NDS for review

Seattle Genetics, Inc. announced today that the validation period is complete and Health Canada has accepted for review its New Drug Submission (NDS) for the use of ADCETRIS (brentuximab vedotin) in relapsed Hodgkin lymphoma (HL) and systemic anaplastic large cell lymphoma.

Governor Tom Wolf announces new initiative to improve care for seniors in Pennsylvania

Today, Governor Tom Wolf unveiled a package of legislative and budgetary actions to provide choice and protections for seniors as they age. Governor Wolf, the Department of Human Services and the PA Department of Aging are committed to increasing opportunities for seniors to receive care in a home or community-based setting.

Critical Diagnostics' high sensitivity Presage ST2 Assay receives CE Mark approval

Critical Diagnostics announced today that it has received CE (Conformité Européenne) Mark for its high sensitivity Presage ST2 Assay and is commencing commercialization in Europe. The product is indicated for use as an aid in risk stratification of patients with heart failure or acute coronary syndrome. This regulatory milestone marks the first time that an assay has become commercially available for the clinical measurement of the biomarker soluble ST2.

European Commission and Japan approve once-daily dual bronchodilator Ultibro Breezhaler (QVA149) nearly simultaneously, for COPD patients

Novartis announced today that the European Commission approved once-daily Ultibro® Breezhaler® (indacaterol 85 mcg / glycopyrronium 43 mcg) as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD). In addition, the Japanese Ministry of Health, Labour and Welfare (MHLW) approved once-daily Ultibro® Inhalation Capsules (glycopyrronium 50 mcg / indacaterol 110 mcg), delivered through the Breezhaler® device, for relief of various symptoms due to airway obstruction in chronic obstructive pulmonary disease (COPD). Ultibro® Breezhaler® / Ultibro® Inhalation Capsules were developed under the name QVA149.

Billie Lynn North, OTR/L - Occupational Therapist in Airville, PA